ArticleGenetics and molecular biology2026
LncRNAs as regulators of chemoresistance and chemosensitivity in triple-negative breast cancer.
Article in Genetics and molecular biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Triple-negative breast cancer (TNBC) is the most aggressive molecular subtype of breast cancer, characterized by significant heterogeneity and high recurrence rates. Due to this heterogeneity, TNBC often develops resistance to chemotherapy, leading to aggressive clinical behavior and poor prognosis. Long non-coding RNAs (lncRNAs), defined as RNAs longer than 500 nucleotides that act at both transcriptional and post-transcriptional levels, influence therapeutic responses in TNBC through various molecular mechanisms, thereby directly impacting treatment effectiveness and patient outcomes. Importantly, lncRNAs have a dual, context-dependent role in TNBC, either promoting chemoresistance or enhancing chemosensitivity by functioning as competing endogenous RNAs, regulating epigenetic processes, stabilizing mRNAs and proteins, and affecting DNA damage repair, apoptosis, autophagy, epithelial-mesenchymal transition, and pro-survival signaling pathways. These functions indicate their potential as therapeutic targets and biomarkers for personalized treatment. In this review, we examine the biological functions of lncRNAs in TNBC, highlighting their molecular mechanisms and clinical significance. We also review evidence on how lncRNAs contribute to therapeutic resistance and sensitivity and explore emerging perspectives on their potential as biomarkers and therapeutic targets for TNBC management.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.